Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 23, 2022
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Journal: The New England journal of medicine
Published: April 21, 2021
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 15, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 03, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Journal: The oncologist
Published: June 27, 2019
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
Journal: JNCI cancer spectrum
Published: May 16, 2019
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Journal: Clinical breast cancer
Published: November 14, 2018
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Journal: Breast cancer research and treatment
Published: March 20, 2018
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2- advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial.
Journal: Breast cancer research and treatment
Published: December 22, 2017
Impact of race and tumor subtype on second malignancy risk in women with breast cancer.
Journal: SpringerPlus
Published: December 18, 2015
Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.
Journal: Investigational new drugs
Published: August 01, 2013
Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 09, 2013
Last Updated: 09/26/2026